Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06649162
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-17
Brief Title:
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease NAFLD in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of DapagliflozinPioglitazone Combination Therapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multi-center Prospective Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease NAFLD in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of DapagliflozinPioglitazone Combination Therapy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease NAFLD in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of DapagliflozinPioglitazone combination therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None